Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study.

ABSTRACT: Vaccination constitutes the best long-term solution against Coronavirus Disease-2019; however, vaccine-derived immunity may not protect all groups equally, and the durability of protective antibodies may be short. We evaluate Spike-antibody responses following BNT162b2 or ChAdOx1-S vaccination amongst SARS-CoV2-naive adults across England and Wales enrolled in a prospective cohort study (Virus Watch). Here we show BNT162b2 recipients achieved higher peak antibody levels after two doses; however, both groups experience substantial antibody waning over time. In 8356 individuals submitting a sample ≥28 days after Dose 2, we observe significantly reduced Spike-antibody levels following two doses amongst individuals reporting conditions and therapies that cause immunosuppression. After adjustin

SUBMITTER: Shrotri M 

PROVIDER: S-EPMC9526787 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature